ArticleFrontiers in neurology2021
New Anti-CGRP Medications in the Treatment of Vestibular Migraine.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- CGRP-Targeting Therapies in Vestibular Migraine: A Synthesis of Observational Evidence with Direction-of-Effect Analysis.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Prophylactic Management of Vestibular Migraine: A Systematic Review.Annals of clinical and translational neurology · 2025Pooled it
- Vestibular migraine treatment: a comprehensive practical review.Brain : a journal of neurology · 2022Pooled it
- CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence?European journal of neurology · 2026Review
- Cochlear Functional Changes and CGRP Modulation in a Chronic Nitroglycerin Migraine-Like Rat Model.The European journal of neuroscience · 2026Article
- Migraine and auditory dysfunction: beyond comorbidity.Journal of neurology · 2026Review
- Seasickness, Sea Legs, and Gravity: Suppression of Motion Sickness, Development of Sea Legs, The Role of the Striated Organelle in the Vestibular Efferent System.Audiology research · 2026Article
- Electrophysiological Characterization of Murine Vestibular Efferent Neurons and Modulation by Acute Peripheral Vestibular Deprivation.Neuroscience bulletin · 2026Article
- The efficacy of rimegepant for the acute treatment of vestibular migraine.Scientific reports · 2026Article
- Effectiveness of rimegepant in vestibular migraine: a prospective self-controlled cohort study.The journal of headache and pain · 2025Article
- Insights into Vestibular Migraine: Diagnostic Challenges, Differential Spectrum and Therapeutic Horizons.Journal of clinical medicine · 2025Review
- Article
- Repetitive transcranial magnetic stimulation for vestibular migraine in women of reproductive age: a retrospective propensity score-matched study.Frontiers in neurology · 2025Article
- Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population.CNS drugs · 2024Observational
- Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- A Vestibular Challenge Combined with Calcitonin Gene-Related Peptide (CGRP) Promotes Anxiety-Like Behaviors.eNeuro · 2024Article
- Focused Update on Migraine and Vertigo Comorbidity.Current pain and headache reports · 2024Review
- Vestibular Migraine Pathophysiology and Treatment: a Narrative Review.Current pain and headache reports · 2024Review
- The dissociation between pathological caloric testing and a normal video head impulse test helps differentiate between Menière's disease, vestibular migraine, and other vestibular disorders: a confirmatory study in a large cohort of 2,101 patients.Frontiers in neurology · 2024Article
- Vestibular Migraine Therapy: Update and Recent Literature Review.Audiology research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVestibular migraine (VM) is a condition associated with migraine headache, vertigo, dizziness, and balance disturbances. Treatment options are limited. It is unknown if new calcitonin gene-related peptide (CGRP) migraine medications have efficacy in treating VM.
methodsWe retrospectively reviewed all patients with VM who were prescribed one of the new CGRP medications between January 2016 and July 2020. In total, 28 patients met the inclusion criteria. We specifically evaluated the "older" CGRP medications including erenumab, galcanezumab, fremanezumab, and ubrogepant. Medical records for subsequent visits were assessed to monitor improvement described by patients.
resultsOf the 28 patients identified, three were lost to follow up. For the remaining 25 patients, we divided the patients based on a scale of "significant improvement," "moderate improvement," "mild improvement," or "no improvement." In total 21 of 25 patients demonstrated some level of improvement in their VM symptoms with 15 having moderate to significant improvement.
conclusionResults demonstrated a trend toward improvement, suggesting that the CGRP medications appear to be a decent treatment option for VM. A prospective study evaluating CGRP medications in patients with VM would provide further information about this treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.